Lead Product(s) : Petrelintide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zealand Enrolls First in ZUPREME-2 Trial of Petrelintide for Obesity And T2D
Details : ZP8396 (petrelintide) is a long-acting amylin analog suitable for once-weekly subcutaneous administration that has been designed for the treatment of obesity.
Product Name : ZP8396
Product Type : Peptide
Upfront Cash : Inapplicable
April 24, 2025
Lead Product(s) : Petrelintide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Petrelintide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zealand Completes Phase 2b Enrollment for Petrelintide in Obesity
Details : ZP8396 (petrelintide) is a long-acting amylin analog suitable for once-weekly subcutaneous administration that has been designed for the treatment of obesity.
Product Name : ZP8396
Product Type : Peptide
Upfront Cash : Inapplicable
March 17, 2025
Lead Product(s) : Petrelintide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Petrelintide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zealand Pharma Enrolls First Participant in Phase 2b ZUPREME-1 Trial of Petrelintide
Details : ZP8396 (petrelintide) is an potent long-acting amylin analogue designed to improve solubility, minimize fibrillation, holdin a potential for the treatment of overweight.
Product Name : ZP8396
Product Type : Peptide
Upfront Cash : Inapplicable
December 10, 2024
Lead Product(s) : Petrelintide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Monlunabant
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Novo Nordisk A/S: Monlunabant Phase 2a Trial in Obesity Completed
Details : INV-202 (monlunabant) is an inverse agonist of the CB1 receptor being investigated for obesity and metabolic syndrome.
Product Name : INV-202
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 20, 2024
Lead Product(s) : Monlunabant
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dapiglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zealand Pharma Reports Positive Results from Phase 1b Trial of Dapiglutide
Details : ZP7570 (dapiglutide), a long-acting GLP-1/GLP-2 receptor dual agonist, it is being developed for weight management in obese patients.
Product Name : ZP7570
Product Type : Peptide
Upfront Cash : Inapplicable
September 09, 2024
Lead Product(s) : Dapiglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dapiglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Goldman Sachs International
Deal Size : $900.0 million
Deal Type : Public Offering
Zealand Pharma Launches Equity Offering Raising USD 900 Million / DKK 6.257 Billion
Details : The net proceeds from the Offering are intended to advance ZP7570 (dapiglutide), a GLP-1/GLP-2 receptor dual agonist in phase 2 trials for obesity patients.
Product Name : ZP7570
Product Type : Peptide
Upfront Cash : Undisclosed
June 25, 2024
Lead Product(s) : Dapiglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Goldman Sachs International
Deal Size : $900.0 million
Deal Type : Public Offering
Lead Product(s) : Dapiglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Goldman Sachs International
Deal Size : $1,000.0 million
Deal Type : Public Offering
Zealand Pharma Completes Upsized Equity Offering Raising $1 Billion in Gross Proceeds
Details : The net proceeds from the Offering are intended to advance ZP7570 (dapiglutide), a GLP-1/GLP-2 receptor dual agonist in phase 2 trials for obesity patients.
Product Name : ZP7570
Product Type : Peptide
Upfront Cash : Undisclosed
June 25, 2024
Lead Product(s) : Dapiglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Goldman Sachs International
Deal Size : $1,000.0 million
Deal Type : Public Offering
Lead Product(s) : Dapiglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zealand Pharma Shares Results from DREAM Trial of Dapiglutide in Obesity
Details : ZP7570 (dapiglutide) is a first-in-class peptide, long-acting, dual GLP-1 /GLP-2 receptor agonist and is being developed for the potential treatment of obesity.
Product Name : ZP7570
Product Type : Peptide
Upfront Cash : Inapplicable
May 23, 2024
Lead Product(s) : Dapiglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tesofensine,Metoprolol Tartrate
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Saniona's Clinical Trial in Hypothalamic Obesity Published in Scientific Journal
Details : Tesomet (tesofensine), is a novel, proprietary molecule, and investigational fixed-dose combination therapy of, a triple monoamine reuptake inhibitor and metoprolol (a beta-1 selective blocker).
Product Name : Tesomet
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 23, 2022
Lead Product(s) : Tesofensine,Metoprolol Tartrate
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tesofensine,Metoprolol Tartrate
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Saniona Initiates Phase 2b Clinical Trial of Tesomet for Hypothalamic Obesity
Details : The initiation of this Phase 2b clinical trial of tesomet represents the culmination of the significant work and primary endpoint of study is the percentage change in body weight from baseline to week 36.
Product Name : Tesomet
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 17, 2021
Lead Product(s) : Tesofensine,Metoprolol Tartrate
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable